Docetaxel-induced hand foot syndrome: “No dose is a safe dose”

Jain, Ankit; Dubashi, Biswajit

doi:10.4103/0976-500X.95534

Case ReportJournal of Pharmacology and PharmacotherapeuticsVol. 3 | Issue 2 | 2012 | pp. 200–201Open access

Docetaxel-induced hand foot syndrome: “No dose is a safe dose”

¹^*,
¹

¹ Department of Medical Oncology, Jawaharlal Institute of Post Graduate Medical Education and Research, Puducherry 6, India Case Report.

Correspondence: Ankit Jain
Department of Medical Oncology, Jawaharlal Institute of Post Graduate Medical Education and Research, Puducherry 6, India Case Report.

Published:: Jan 1, 2012
DOI:: 10.4103/0976-500X.95534

How to cite

Jain, A., & Dubashi, B. (2012). Docetaxel-induced hand foot syndrome: “No dose is a safe dose”. Journal of Pharmacology and Pharmacotherapeutics, 3(2), 200–201. https://doi.org/10.4103/0976-500X.95534

Abstract

Docetaxel is an important chemotherapeutic agent used in the management of many solid tumors. The most important side effect of this drug is myelosupression. We report a case of carcinoma breast that developed severe hand-foot syndrome at 75 mg/m2 doses of docetaxel. The exact mechanism of this side effect in not known. All the physicians using this drug must be aware of this side effect.

Keywords

Subject

Article metadata

Title	Docetaxel-induced hand foot syndrome: “No dose is a safe dose”
Authors	Ankit Jain; Biswajit Dubashi
Affiliations	Department of Medical Oncology, Jawaharlal Institute of Post Graduate Medical Education and Research, Puducherry 6, India Case Report.
Journal	Journal of Pharmacology and Pharmacotherapeutics
Volume / Issue	Vol. 3, Issue 2 (2012)